GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (NAS:LSTA) » Definitions » Ending Cash Position

Lisata Therapeutics (Lisata Therapeutics) Ending Cash Position : $22.59 Mil (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Lisata Therapeutics Ending Cash Position?

Lisata Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 was $22.59 Mil.

Lisata Therapeutics's quarterly Ending Cash Position increased from Jun. 2023 ($23.69 Mil) to Sep. 2023 ($32.43 Mil) but then declined from Sep. 2023 ($32.43 Mil) to Dec. 2023 ($22.59 Mil).

Lisata Therapeutics's annual Ending Cash Position increased from Dec. 2021 ($24.65 Mil) to Dec. 2022 ($32.15 Mil) but then declined from Dec. 2022 ($32.15 Mil) to Dec. 2023 ($22.59 Mil).

Lisata Therapeutics Ending Cash Position Historical Data

The historical data trend for Lisata Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lisata Therapeutics Ending Cash Position Chart

Lisata Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.03 16.51 24.65 32.15 22.59

Lisata Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.15 28.16 23.69 32.43 22.59

Lisata Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Lisata Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=32.154+-9.561
=22.59

Lisata Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=32.428+-9.835
=22.59

Lisata Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Lisata Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Lisata Therapeutics (Lisata Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (NAS:LSTA) » Definitions » Ending Cash Position
Comparable Companies
SYBX AIM BIOR LUMO ZIVO CNTX NRXS NRSN PYPD TCRT OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920
Website
https://www.lisata.com
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.
Executives
David W. Slack director, officer: President & CBO 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Heidi Henson director 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Mohammad Azab director C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Erkki Ruoslahti director P.O. BOX 544, BUELLTON CA 93427
Steven S Myers director 4695 MACAUTHUR COURT, EIGHTH FLOOR, NEWPORT BEACH CA 92660
Kristen K Buck officer: EVP, R&D and CMO 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Todd C Girolamo officer: CLO, SVP of Corp Dev 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Michael H. Davidson director OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Cynthia Schwalm director C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709
David J Mazzo director, officer: Chief Executive Officer 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Joseph Talamo officer: SVP and CFO CALADRIUS BIOSCIENCES, INC., 800 WESTCHESTER AVENUE. STE N341, RYE BROOK NY 10573
Douglas W Losordo officer: See Remarks 13 FOX MEADOW RD, SCARSDALE NY 10583
Anford 10 percent owner P.O. BOX 5039, SIOUX FALLS SD 57117
Health Sanford 10 percent owner P.O. BOX 5039, SIOUX FALLS SD 57117